Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NK/T Cell Lymphoma Nos Clinical Trial

Official title:
Sintilimab With P-GemOx (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (ENKTL): a Single Arm, Open, Multicenter, Phase II Study

Status Recruiting

Clinical Trial Summary

The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diagnosed advanced extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04127227
Study type	Interventional
Source	Sun Yat-sen University
Contact	Qingqing Cai, MD
Phone	0086-20-87342823
Email	caiqq@sysucc.org.cn
Status	Recruiting
Phase	Phase 2
Start date	October 9, 2019
Completion date	October 9, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04484506` - Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma	Phase 2
Recruiting	`NCT04365036` - A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)	Phase 3
Not yet recruiting	`NCT05316246` - Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma	Phase 2
Recruiting	`NCT04231370` - Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma	Phase 2